Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act
Summary
This law, signed in February 2020, temporarily extended the DEA's emergency scheduling of fentanyl-related substances as Schedule I until May 2021 and mandated a GAO study. It is a procedural extension with no direct financial impact on publicly traded companies, as it does not authorize or appropriate any funding.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The law is a procedural extension of existing DEA scheduling authority, not a new spending or regulatory program.
- 2.No funding is authorized or appropriated, meaning zero direct financial impact on any sector.
- 3.The GAO study requirement is informational and does not create market-moving obligations for any company.
Market Implications
No market implications. The law is a routine procedural extension of existing drug scheduling authority. It does not affect the revenue, costs, or competitive positioning of any publicly traded company. Investors should not expect any market movement from this legislation.
Full Analysis
The Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act (Public Law 116-114) was signed into law on February 6, 2020, during the 116th Congress. The bill extended the DEA's temporary scheduling order for fentanyl-related substances as Schedule I controlled substances until May 6, 2021, and directed the Government Accountability Office to study the classification, research, and importation of these substances. The bill was sponsored by Sen. Lindsey Graham (R-SC) and had bipartisan cosponsorship, passing the Senate by unanimous consent and the House without recorded opposition. The law does not authorize or appropriate any funding; it is a regulatory extension and a study mandate. As such, there is no direct money trail for investors to track. The law's impact on the pharmaceutical or healthcare sector is indirect and minimal, as it maintains the status quo for scheduling of fentanyl analogues without creating new market opportunities or liabilities. No publicly traded companies are directly affected by this procedural action, and no convergence with other legislative or procurement signals is evident from the provided data.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Extending Temporary Emergency Scheduling of Fentanyl Analogues Act
Extension of Continuing Appropriations Act, 2022
STOP Nitazenes Act
Preventing the Financing of Illegal Synthetic Drugs Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →